|Description||SKF-86002 is a p38 MAP kinase inhibitor, the IC50 is 0.1 - 1 μM. It potently inhibits LPS-induced IL-1 and TNF-α production in human monocytes, the IC50 is1 μM. It also acts as an inhibitor of both cyclooxygenase (COX) and 5-lipoxygenase (5-LO). In vitro: SKF-86002 inhibited prostaglandin H2 synthase activity, the IC50 is 120 mM as well as prostanoid production by rat basophilic leukemia cells, the IC50 is mM and its sonicate ( the IC50 is 100 mM and human monocytes (the IC50 is 1 mM. It inhibited the generation of dihydroxyeicosatetraenoic acid and 5-hydroxyeicosatetraenoic acid by a high speed supernatant fraction of RBL-1 cells (the IC50 is 10 mM). It blocked superoxide anion production in response to FMLP and reduced adhesion and chemotaxis in response to PAF or FMLP.|
|Quantity||Milligram to gram|
|Quality Standard||In-house standard|
Skepinone-L is a selective p38α-MAPK inhibitor with IC50 of 5 nM.
PH-797804 is a diarylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase. PH-797804 exhibited exceptionally high specificity against MAP kinases ...
SD-06 is an inhibitor of p38α (IC50=170 nM).
SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated...
CHMFL-ABL-053 is an orally available, small molecule multi-kinase inhibitor for BCR-ABL (IC50= 70 nM),SRC (IC50 = 90 nM) and p38 kinases (IC50 = 62 nM). CHMFL-A...
VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that ...
RPR-200765A Mesylayte, a potent and selective inhibitor of p38 MAP kinase (IC50 = 50 nM), could exhibit a profile of disease modifying activity in rheumatoid ar...
TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK...
SKF-86002 is a p38 MAP kinase inhibitor, the IC50 is 0.1 - 1 μM. It potently inhibits LPS-induced IL-1 and TNF-α production in human monocytes, the IC50 is1 μM....
Talmapimod, also known as SCIO-469, is an orally bioavailable, small-molecule, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodula...
LY2228820 dimesylate is a highly selective small molecule inhibitor of p38α(IC50=7 nM) and p38β mitogen-activated protein kinases (MAPKs).
p38 MAPK-IN-1, a naphthyridine N-oxide, is a novel potent and selective inhibitor of p38 MAPK and it was found to have proper balance between potency and pharma...
Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the developm...
SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM.
Doramapimod (BIRB 796) is a member of the N-pyrazole-N'-naphthly urea class of p38MAPK inhibitors, which binds to the kinase with both slow association and diss...
SB 203580 hydrochloride
SB 203580 hydrochloride is a water-soluble form of the potent MAP kinase inhibitor SB 203580. It is a selective inhibitor of p38 mitogen-activated protein kinas...
Acumapimod is a P38 mitogen-activated protein kinase inhibitor with IC50 value of less than 1 μM for p38α. Phase II clinical trials for the treatment of Chronic...
SB202190, also named FHPI, under the IUPAC name 4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one, is a pyridinyl imid...